Treat-to-target is a widely used approach for rheumatoid arthritis, in which rheumatologists prescribe treatments to reach established benchmarks of disease activity.1 Is it time for a similar approach for fibromyalgia treatment, even though its pathogenesis, disease-activity measures and treatment algorithms are less well understood? Three fibromyalgia researchers present their case in a new paper, “Treat-to-Target…
Search results for: back pain
Hemoptysis in a Young Indian Male
A 22-year-old Indian male presented to the emergency department with hemoptysis. A month prior, he had presented to an urgent care center complaining of cough with occasional episodes of blood-tinged sputum in the morning. He was diagnosed with community-acquired pneumonia based on a chest X-ray without laboratory testing and was prescribed levofloxacin. A few days…
FDA Approves Lesinurad + Allopurinol
Duzallo, a combination of lesinurad and allopurinol, was approved by the FDA in August to treat hyperuricemia associated with gout…
Acupuncture & Electrotherapy May Help Patients after Total Knee Arthroplasty
A new review examined how drug-free interventions affect pain relief and analgesic consumption for patients who have had knee surgery. Although little evidence shows these treatments reduce actual pain, electrotherapy and acupuncture may help patients delay their postoperative use of opioids…
Abatacept Approved for Psoriatic Arthritis in Adults; Sirukumab Approval Stalls
Abatacept Approved for Adult PsA On June 30, the U.S. Food and Drug Administration (FDA) approved abatacept (Orencia) to treat adults with active psoriatic arthritis (PsA).1 Abatacept is available as both an intravenous formulation and a subcutaneous injection.2 The approval was based on results of two randomized, double-blind, placebo-controlled trials, PsA-I and PsA-II, during which…
Predictive Value of Imaging Studied for Calcium Crystal Deposition in Rheumatic Diseases
MADRID—Calcification in osteoarthritis (OA) involves a series of pathways and interactions that feed off each other in a process that bears some resemblance to the transformation of cartilage to bone that takes place in the embryonic stage of human development, a researcher said here at the 2017 Annual European Congress on Rheumatology (EULAR). “My hypothesis…
ARHP Stands Up for Members and Patients
Editor’s note: The new Pillar Talk column is developed by the ARHP Executive Committee in an effort to share information about ongoing activities related to our four pillars: Education, Practice, Research and Advocacy. ARHP volunteers are actively involved in the ACR’s efforts to advocate for the care of our patients and the rheumatology professionals who…
Ibuprofen More Likely to Raise BP than Naproxen or Celecoxib
NEW YORK (Reuters Health)—Ibuprofen boosts blood pressure (BP) more than naproxen or celecoxib in patients who take non-steroidal anti-inflammatory drugs (NSAIDs) to treat arthritis, according to a new substudy from the PRECISION trial. “These drugs are different with regard to BP, and ibuprofen is the worst,” Dr. Frank Ruschitzka of University Hospital Zurich in Switzerland,…
Medication Adherence for Osteoporosis Prevention
In a new study, patients taking denosumab had greater treatment adherence over two years than patients on alendronate and other anti-osteoporosis agents…
ACR/ARHP Makes Another Push to Repeal Medicare Therapy Caps
H.R. 807, Medicare Access to Rehabilitation Services Act of 2017, will be one of the key issues discussed when members of the ACR’s Government Affairs Committee (GAC) visit Capitol Hill Sept. 26 during the annual Advocates for Arthritis event. This bill—as well as its companion bill in the Senate, S. 253—is aimed at repealing the…
- « Previous Page
- 1
- …
- 104
- 105
- 106
- 107
- 108
- …
- 156
- Next Page »